MoonLake Immunotherapeutics
MLTX
$16.77
$0.040.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.89% | -97.02% | -127.56% | -192.14% | -513.21% |
| Total Depreciation and Amortization | 106.32% | 112.25% | 116.96% | 15.24% | 1.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 329.25% | 103.11% | -16.01% | 44.52% | -41.84% |
| Change in Net Operating Assets | 100.15% | 158.72% | 77.65% | 87.03% | 39.22% |
| Cash from Operations | -21.29% | -76.23% | -95.52% | -155.15% | -292.68% |
| Capital Expenditure | 100.00% | 100.00% | -- | 83.49% | 38.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 79.67% | 51.34% | 200.58% | 296.84% | -225.61% |
| Cash from Investing | 79.70% | 51.68% | 200.58% | 295.27% | -226.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 47,843.71% | 427.47% | -- | -99.81% | -99.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 47,843.71% | 162.30% | -- | 43.44% | -99.47% |
| Foreign Exchange rate Adjustments | -78.54% | 12.31% | 8,282.35% | -291.30% | 555.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.69% | 34.05% | 130.36% | 1,153.30% | -246.78% |